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throughout the sensitivity analyses. CONCLUSIONS: Based on evidence from the
PLATO study, treating a broad spectrum of ACS patients with ticagrelor for one year
seems to offer a cost-effective option in the German health care setting compared
with clopidogrel.
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OBJECTIVES:We examined sponsorship of published economic evaluations of sta-
tin use for cardiovascular (CDV) prevention and evaluated whether funding is as-
sociated with study conclusions.METHODS:A systematic review was conducted in
PubMed/MEDLINE (up to June 2011) to identify cost-effectiveness analyses of statin
use for CDV prevention reporting outcomes as cost per life years gained and/or
quality-adjusted life years. The review was restricted to 6 licensed statins: simva-
statin, pravastatin, fluvastatin, lovastatin, atorvastatin and rosuvastatin. We clas-
sified study intervention data as follows: 1) comparators: statin-statin or statin-
non active drug comparisons, and 2) primary or secondary CDV prevention. We
established relationships between funding source (industry- vs. non-industry-
sponsored studies) and qualitative conclusions (favorable, unfavorable or neutral)
by means tests of differences between proportions. RESULTS: Overall, 72 studies
were included. Thirty-six studies (50%) were carried out in Europe and 31 (43%) in
North America. Fourty-seven (65%) articles compared statins versus non-active
drugs. The category of CDV prevention was distributed as follows: 46% secondary,
39% primary and 15% both. Considering funding source, 64% were industry-spon-
sored studies. For studies evaluating primary CDV prevention, industry-sponsor-
ship was much less likely to have unfavorable or neutral conclusions (0% vs. 59%;
p0.001). Conversely, these differences were not detected for studies evaluating
secondary CDV prevention (0% versus 13%; p0.212). CONCLUSIONS: Our results
suggest that sponsorship of economic evaluation of statins is associated with their
qualitative conclusions in primary CDV prevention.
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OBJECTIVES: The PLATO trial showed that in patients with acute coronary syn-
dromes (ACS) treatment with ticagrelor compared with clopidogrel significantly
reduced the rate of myocardial infarction, stroke, or death from vascular causes
without a significant increase in the rate of overall major bleeding. The aim of this
analysis is to estimate long-term cost-effectiveness of treating ACS patients with
ticagrelor from a Polish health care perspective. METHODS: The model used is a
two-part decision-analytic model, comprising a one-year decision tree and a long-
term Markov model. Model estimates lifetime costs, LYGs and QALYs of treating
ACS patients for one year with ticagrelor plus ASA compared with clopidogrel plus
ASA. The model is based on the results observed in the PLATO study and populated
with the overall clinical, resource use and quality of life results from PLATO trial.
Unit costs were derived from the National Health Fund in Poland. A generic clopi-
dogrel price of 0,92 PLN per day, and a ticagrelor price of 10,85 PLN per day were
applied. Standard mortality rates for the Polish population were used. Data are
presented in PLN with exchange rate: 1,00 PLN € 0,25. RESULTS: Treatment with
ticagrelor was associated with a QALY gain of 0,11 and a LYG gain of 0,12 compared
with clopidogrel. The incremental cost of ticagrelor treatment was 2814 PLN. The
ICER per QALY gained with ticagrelor compared with clopidogrel was 25 675 PLN,
while the ICER per LYG with ticagrelor was 22 257 PLN. Probabilistic sensitivity
analysis indicates that ticagrelor treatment has a 90% probability of being cost
effective given a willingness of pay threshold of 40 000 PLN. The results are consis-
tent in all ACS subgroups. CONCLUSIONS: Based on clinical and health economic
evidence from the PLATO study, treating ACS patients with ticagrelor for one year
is cost-effective compared with clopidogrel in Polish settings.
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OBJECTIVES: Communication impairment after stroke affects everyday activities
and social participation. Speech and Language therapy (SLT) has waiting lists of 6
months plus in the National Health Service (NHS), implying a high opportunity
cost. The aim was to evaluate the cost effectiveness of SLT versus attention control
(AC), at six months, for people with communication difficulties due to aphasia/
dysarthria following stroke. METHODS: The economic analysis was an integral
component of a randomised, controlled, pragmatic trial comparing SLT (n 85) and
AC (n85). The perspective was the NHS and social care, patients and families. The
time horizon was 6 months (baseline to end of scheduled follow up). Resource use
and health status (EQ-5D) were collected on all participants recruited into the trial.
Utility values were estimated from the EQ-5D and associated population tariffs.
The setting was inpatient and community/primary care in North West England;
data were collected between 2006 and 2010. Unit cost data are for 2008-2009. Re-
gression models estimated incremental or costs and outcomes for the ICER, ad-
justed for predefined covariates. Incremental costs and outcomes were boot-
strapped to derive cost effectiveness acceptability curves, net benefit statistics and
probability that SLT was cost effective. RESULTS: The net cost of SLT was £110 (95%
percentiles: -£640 to £861). The net utility was 0.01 (95% percentiles: -0.03 to
0.04). SLT is only likely to be cost effective if decision makers are willing to pay
£25,000 or more to gain a 1 point increase in utility (p0.50). The cost effectiveness
of SLT depends on the outcome measure used and the baseline severity of stroke.
CONCLUSIONS: The primary and sensitivity analyses indicated a high level of
uncertainty suggesting it is not possible to conclude whether therapy is more or
less cost effective than attention control.
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OBJECTIVES: About 33% of patients develop depression after myocardial infarc-
tion, while 25% of patients with diabetes have depression. Patients with co-morbid
depression have lower treatment compliance and health status, increased health-
care use, social isolation and mortality. This study aimed to systematically review
current economic evidence of non-pharmacological treatment interventions for
patients with CHD or diabetes and co-morbid clinically-relevant depression.
METHODS: The electronic search strategies (conducted in MEDLINE, EMBASE, Psy-
cINFO, CINAHL, NHS EED) combined clinical search terms with terms used by the
UK National Health Service Economic Evaluation Database (NHSEED), to identify
full economic evaluations of the relevant interventions. Pre-specified screening
and inclusion criteria were used. Standardised data extraction and critical ap-
praisal (using NHSEED criteria) were conducted. RESULTS: Excluding duplicates,
1336 studies for CHD and 1281 for diabetes were screened. Four economic evalua-
tions were identified (two for diabetes and two for CHD). The studies found that the
interventions improved health status, reduced depression and were cost-effective
compared to usual care. Both CHD studies were UK-based and used home-based
cognitive behavioural programmes. The net costs were -£42 to £2, the net QALY
gains were 0.006 to 0.009. The diabetes studies were based on US-based and used
stepped collaborative care programmes delivered by specialised nurses. The net
costs were -$1378 to $216, the net gains in depression free days were 53 to 115.
CONCLUSIONS: The review highlighted the paucity of evidence in this area and
associated uncertainty. Four small studies indicated the potential of psychological
interventions to improve the quality of life, reduce depression and be cost-effective
compared to usual care. Robust and well-designed economic evaluations of non-
pharmacological treatment interventions for patients with co-morbid depression
are needed. An economic model is being developed to synthesise data from various
sources to explore this further.
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OBJECTIVES: To estimate the cost-effectiveness of closing the statin ‘treatment
gap’ in the secondary prevention of coronary artery disease (CAD) in Australia.
METHODS:We developed a decision-analysis Markov model with yearly cycles and
the following health states: ‘Alive’ and ‘Dead’. Using data from the Australian
Reduction of Atherothrombosis for Continued Health (REACH) registry, the model
compared current statin coverage (82%) in the secondary prevention of CAD (‘Cur-
rent’ group) with a hypothetical situation of 100% coverage (‘Improved’ group). The
18% gap was filled with use of generic statins. Data from a recent meta-analysis
were used to estimate the benefits of statin use in terms of reducing recurrent
cardiovascular events and death. Government-reimbursement data from 2011 was
used to calculate direct healthcare costs. The cost of the intervention to improve
statin coverage was assumed to be $250 per person. Years of life lived and costs
were discounted at 5% annually. RESULTS: Among the 2058 subjects in the ‘Cur-
rent’ group, the model estimated that there would be 106 non-fatal myocardial
infractions, 68 non-fatal strokes and 275 deaths over five years. In the ‘Improved’
group, within which all subjects took statins, the corresponding numbers were 101,
65, and 259, equating to numbers needed to treat of 426, 639, and 127, respectively.
Over the five years, there would be 0.018 life years gained (discounted) at a net cost
of AUD $546 (discounted) per person. These equated to an incremental cost-effec-
tiveness ratio (ICER) of AUD $29,717 per life year gained. CONCLUSIONS: The re-
sults suggest that for patients with CAD, maximizing coverage with statins, in line
with evidence-based recommendations, represents a cost-effective means of sec-
ondary prevention.
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OBJECTIVES: To evaluate the cost-effectiveness of one-year treatment with clopi-
dogrel plus aspirin compared to aspirin alone in patients without ST-segment el-
evation (NSTEMI) from the Greek third-party-payer perspective. METHODS: A
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